Enjoy complimentary customisation on priority with our Enterprise License!
“The Irritable Bowel Syndrome Market is poised to grow by USD 779.89 millionn during 2022-2026, accelerating at a CAGR of 10.09% during the forecast period”
Irritable Bowel Syndrome Market (IBS) is a common disorder that affects the stomach and intestines, also called the gastrointestinal tract. Symptoms include cramping, abdominal pain, bloating, gas, and diarrhea or constipation, or both. IBS is a chronic condition that you'll need to manage long-term.
Technavio market report provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 15 vendors. Furthermore, this report extensively covers the market segmentation by type IBS-D ,IBS-C and IBS-M and geography of North America, Europe, Asia, and ROW . The market report also offers information on several market vendors, including AbbVie Inc., Alfasigma Spa, Astellas Pharma Inc., AstraZeneca Plc, Bausch Health Companies Inc., Ironwood Pharmaceuticals Inc., Mallinckrodt Plc, Novartis AG, Sebela Pharmaceuticals Inc., and Teva Pharmaceutical Industries Ltd. among others.
Download Report Sample to Unlock the Irritable Bowel Syndrome Market Size for the Forecast Period and Other Important Statistics
Our Technavio Research categorizes the report belonging to Pharmaceuticals, Biotechnology and Life Sciences and with a segment of IBS market. Technavio is based on four simple principles: easy-to-access reports, robust industry coverage, a focus on new and emerging technologies, and competitive pricing. We believe in helping companies and executives become better equipped to make faster, sounder, and more effective decisions.
Technavio is a global technology research and advisory company. We use a proprietary Research Methodology tailored to each market we cover. Unlike most vendors that provide similar reports, our team of Industry Experts constantly validates our data, assumptions, and conclusions based on in-depth research and over 50 years of combined experience in the IT Industry. Our data is completely original: it has not been aggregated or replicated. This creates a unique opportunity for you to obtain a comprehensive view of the current state of the market as well as provide deep insights into future outlook areas.
Irritable bowel syndrome is a medical condition that can cause abdominal pain, bloating, gas and diarrhea. The most common treatment for irritable bowel syndrome is dietary and lifestyle changes such as diet modifications such as avoiding fatty foods or eating smaller portions of certain types of food such as carbohydrates or proteins, along with the consumption of antacids containing magnesium that might help relieve some of the symptoms. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic's impact on the smart room heater industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.^^^Our researcher studied the historical data for years, with 2020 as the base year, and 2021 as the estimated year, and produced drivers, trends, and challenges for the market. In the COVID-19 pandemic, the demand of the irritable bowel syndrome market has been impacted a lot accelerating but a holistic analysis of drivers will help in exact demands and refining marketing strategies to gain a competitive advantage.
Key Irritable Bowel Syndrome Market Driver
One of the key factors driving the global irritable bowel syndrome market growth is the unhealthy lifestyle habits of people. The fast-paced world has compelled people to opt for takeaway food or fast food, which has high-fat content that is one of the primary causes of acidity that increases the risk of developing irritable bowel syndrome. According to the Centers for Disease Control and Prevention (CDC), during 2015-2019, 44.7% of adults in the US consumed fast food on any given day. Other factors causing the condition are the consumption of alcohol or tobacco in cigarettes/cigars. According to the CDC's January 2021 report, excessive alcohol use causes approximately 95,000 deaths in the US each year. These incidences are increasing the need for treatment for irritable bowel syndrome, which will positively impact the market in focus during the forecast period.
Key Irritable Bowel Syndrome Market Challenge
The high availability of counterfeit drugs is one of the key challenges to the global irritable bowel syndrome market growth. According to the US FDA, many illegal websites are selling unapproved drugs. These sellers go unnoticed owing to the inadequate regulations, especially in developing countries such as India, which will negatively impact the health of consumers and the growth of the market. For instance, according to a news article in the Times of India newspaper published in March 2018, 90,000 capsules and tablets of antacids and multivitamins were seized in Delhi by the crime branch. Therefore, the availability of counterfeit products and inadequate regulations will make market penetration difficult for key vendors, which will hamper the global irritable bowel syndrome market growth.
This irritable bowel syndrome market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.
The parent, the global pharmaceuticals market, covers products and companies engaged in the R&D or production of generic drugs, non-generic drugs, and veterinary drugs. Technavio calculates the global healthcare market size based on the combined revenue generated by manufacturers/providers of equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services.
The vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading smart room heater market vendors such as
In this report, we have profiled the key players in the irritable bowel syndrome market. The report provides illustrative insights into the scope and scale of operations, product portfolio and revenue earned by these companies operating in the global irritable bowel syndrome market. The report also evaluates this market's current status with respect to leaders, competitors, and potential risks.
Our report provides extensive information on the value chain analysis for the irritable bowel syndrome market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
40% of the market's growth will originate from North America during the forecast period. The US is the key market for irritable bowel syndrome market in North America. Market growth in this region will be faster than the growth of the market in Europe and ROW.
The rapid increase in the number of patients with gastrointestinal diseases and disorders owing to an alteration in bowel habits, abdominal pain, a surge in the level of stress, and eating an unhealthy diet will facilitate the irritable bowel syndrome market growth in North America over the forecast period.The growing awareness about digestive disorders, such as IBS, gastric diseases, Crohn’s disease, the rising number of people diagnosed with gallstones (cholecystolithiasis), and associated autoimmune diseases, has led many individuals to undergo regular healthcare tests and check-ups. Therefore, people in the region are aware of irritable bowel syndrome and its challenges, which is encouraging them to opt for diagnosis and treatment. Countries across North America were severely affected by the COVID-19 pandemic in 2020 This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
The rise in the incidence of COVID-19 in countries across the region spurred the manufacturing of several essential drugs to treat COVID-19 patients and reduced the production volume of other therapeutic drugs, including those used in the treatment of IBS. In addition, many pharmaceutical companies present in the region increased their focus on developing COVID-19 vaccines, which lowered the development and production of other therapeutics, including those used in the treatment of IBS.
To gain further insights on the market contribution of various segments Request a PDF Sample
To gain further insights on the market contribution of various segments Request for a FREE sample
The irritable bowel syndrome market share growth by the IBS-D segment will be significant during the forecast period. By 2025, the irritable bowel syndrome market share by the IBS-D will be 49.90% of the total market. The significant increase in the demand for US Food and Drug Administration (FDA) approved drugs such as Xifaxan (rifaximin) and eluxadoline for the treatment of Irritable bowel syndrome will facilitate the growth of the market during the forecast period.
The report provides a near-term to long-term perspective on the trends and forecasts horizon for the anti-venom market. It offers an overview of the key market drivers and restraints, enabling precise identification of key opportunities in each region over the coming years.
Irritable Bowel Syndrome Market Scope |
|
Report Coverage |
Details |
Page number |
120 |
Base year |
2020 |
Forecast period |
2021-2025 |
Growth momentum & CAGR |
Accelerate at a CAGR of 10.09% |
Market growth 2021-2025 |
$ 779.89 million |
Market structure |
Fragmented |
YoY growth (%) |
9.60 |
Regional analysis |
North America, Europe, Asia, and ROW |
Performing market contribution |
North America at 40% |
Key consumer countries |
US, Germany, UK, China, and Japan |
Competitive landscape |
Leading companies, Competitive Strategies, Consumer engagement scope |
Key companies profiled |
AbbVie Inc., Alfasigma Spa, Astellas Pharma Inc., AstraZeneca Plc, Bausch Health Companies Inc., Ironwood Pharmaceuticals Inc., Mallinckrodt Plc, Novartis AG, Sebela Pharmaceuticals Inc., and Teva Pharmaceutical Industries Ltd. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
Executive Summary
Market Landscape
Market Sizing
Five Forces Analysis
Market Segmentation by Type
Market Segmentation by Drug type
Customer landscape
Geographic Landscape
Vendor Landscape
Vendor Analysis
Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.